Related Experiment Video

Updated: Apr 14, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic

Stefan Zeuzem, Reem Ghalib, K Rajender Reddy

    Annals of Internal Medicine
    |April 25, 2015
    PubMed
    Abstract

    Insights

    New interferon- and ribavirin-free regimens are crucial for treating hepatitis C virus (HCV). Grazoprevir-elbasvir demonstrated high sustained virologic response rates (SVR12) in treatment-naive patients, offering a potent new therapeutic option.

    Area of Science:

    • Hepatology
    • Virology
    • Infectious Diseases

    Background:

    • Hepatitis C virus (HCV) infection necessitates novel, interferon- and ribavirin-free treatment regimens.
    • Current treatment limitations drive the search for more effective and tolerable therapies.

    Purpose of the Study:

    • To assess the safety and efficacy of grazoprevir (NS3/4A protease inhibitor) and elbasvir (NS5A inhibitor) combination therapy.
    • Evaluate treatment outcomes in treatment-naive patients with chronic HCV genotypes 1, 4, or 6.

    Main Methods:

    • A randomized, blinded, placebo-controlled trial involving 421 treatment-naive adult patients with HCV genotypes 1, 4, or 6.
    • Patients received oral, once-daily, fixed-dose grazoprevir 100 mg/elbasvir 50 mg for 12 weeks, stratified by fibrosis and genotype.
    • The primary endpoint was the proportion of patients achieving sustained virologic response 12 weeks post-treatment (SVR12).

    Main Results:

    • High SVR12 rates were observed: 95% overall (299/316) in the immediate-treatment group.
    • Specific SVR12 rates included 92% for genotype 1a, 99% for 1b, 100% for genotype 4, and 80% for genotype 6.
    • Adverse events were generally mild, with headache, fatigue, and nausea being most common; no serious drug-related events were reported.

    Conclusions:

    • Grazoprevir-elbasvir achieved high SVR12 rates in treatment-naive patients with HCV genotypes 1, 4, and 6, including those with cirrhosis.
    • This all-oral, fixed-combination regimen is a promising new therapeutic option for chronic HCV infection.
    • Limitations include the absence of an active-comparator arm and a limited number of genotype 4 and 6 cases.

    More Related Videos

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    18.6K
    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.8K

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
    59
    Diseases of the Liver and Gallbladder01:26

    Diseases of the Liver and Gallbladder

    Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
    Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
    2.4K
    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    35
    Retroviruses02:33

    Retroviruses

    Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
    16.0K
    Retrovirus Life Cycles01:10

    Retrovirus Life Cycles

    Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
    50.8K
    Chronic Pancreatitis II: Collaborative Care01:29

    Chronic Pancreatitis II: Collaborative Care

    The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
    Assessment:
    521